One promising study showed that treating T2D patients with application of nasal GLP-1 compound bypasses side effects such as nausea and vomiting of subcutaneous injections of GLP-1 agonists and reduces glycemia [66]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.